|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rahman R, Asombang AW and Ibdah JA:
Characteristics of gastric cancer in Asia. World J Gastroenterol.
20:4483–4490. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Coupland VH, Allum W, Blazeby JM, Mendall
MA, Hardwick RH, Linklater KM, Møller H and Davies EA: Incidence
and survival of oesophageal and gastric cancer in England between
1998 and 2007, a population-based study. BMC Cancer. 12:112012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cidon EU, Ellis SG, Inam Y, Adeleke S,
Zarif S and Geldart T: Molecular targeted agents for gastric
cancer: A step forward towards personalized therapy. Cancers
(Basel). 5:64–91. 2013. View Article : Google Scholar
|
|
5
|
Wang JL, Hu Y, Kong X, Wang ZH, Chen HY,
Xu J and Fang JY: Candidate microRNA biomarkers in human gastric
cancer: A systematic review and validation study. PLoS One.
8:e736832013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Menon V and Povirk L: Involvement of p53
in the repair of DNA double strand breaks: Multifaceted roles of
p53 in homologous recombination repair (HRR) and non-homologous end
joining (NHEJ). Subcell Biochem. 85:321–336. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Melis JPM, van Steeg H and Luijten M:
Oxidative DNA damage and nucleotide excision repair. Antioxid Redox
Signal. 18:2409–2419. 2013. View Article : Google Scholar :
|
|
8
|
Tian H, Gao Z, Li H, Zhang B, Wang G,
Zhang Q, Pei D and Zheng J: DNA damage response - a double-edged
sword in cancer prevention and cancer therapy. Cancer Lett.
358:8–16. 2015. View Article : Google Scholar
|
|
9
|
Vasquez KM: Targeting and processing of
site-specific DNA interstrand crosslinks. Environ Mol Mutagen.
51:527–539. 2010.PubMed/NCBI
|
|
10
|
Wagner AD, Unverzagt S, Grothe W, Kleber
G, Grothey A, Haerting J and Fleig WE: Chemotherapy for advanced
gastric cancer. Cochrane Database Syst Rev. (3):
CD0040642010.PubMed/NCBI
|
|
11
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar
|
|
12
|
Hagan JP and Croce CM: MicroRNAs in
carcinogenesis. Cytogenet Genome Res. 118:252–259. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Suzuki HI, Katsura A, Matsuyama H and
Miyazono K: MicroRNA regulons in tumor microenvironment. Oncogene.
34:3085–3094. 2015. View Article : Google Scholar
|
|
14
|
Jiang C, Chen X, Alattar M, Wei J and Liu
H: MicroRNAs in tumorigenesis, metastasis, diagnosis and prognosis
of gastric cancer. Cancer Gene Ther. 22:291–301. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sobin LH, Gospodarowicz MK and Wittekind
Ch: TNM classification of malignant tumours. 7th edition.
Wiley-Blackwell; Hoboken, NJ: 2009
|
|
16
|
Kalfert D, Pesta M, Kulda V, Topolcan O,
Ryska A, Celakovsky P, Laco J and Ludvikova M: MicroRNA profile in
site-specific head and neck squamous cell cancer. Anticancer Res.
35:2455–2463. 2015.PubMed/NCBI
|
|
17
|
Song P, Yin Q, Lu M, Fu BO, Wang B and
Zhao Q: Prognostic value of excision repair cross-complementation
group 1 expression in gastric cancer: A meta-analysis. Exp Ther
Med. 9:1393–1400. 2015.PubMed/NCBI
|
|
18
|
Yao A, Wang Y, Peng X, Ye R, Wang Q, Qi Y
and Zhou F: Predictive value of excision repair
cross-complementation group 1 expression for platinum-based
chemotherapy and survival in gastric cancer: A meta-analysis. J
Cancer Res Clin Oncol. 140:2107–2117. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wei J, Zou Z, Qian X, Ding Y, Xie L,
Sanchez JJ, Zhao Y, Feng J, Ling Y, Liu Y, et al: ERCC1 mRNA levels
and survival of advanced gastric cancer patients treated with a
modified FOLFOX regimen. Br J Cancer. 98:1398–1402. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hu HB, Kuang L, Zeng XM, Li B, Liu EY and
Zhong MZ: Predictive value of thymidylate synthase expression in
gastric cancer: A systematic review with meta-analysis. Asian Pac J
Cancer Prev. 13:261–267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Faruq O and Vecchione A: microRNA:
Diagnostic Perspective. Front Med (Lausanne). 2:512015.
|
|
22
|
Wu Q, Jin H, Yang Z, Luo G, Lu Y, Li K,
Ren G, Su T, Pan Y, Feng B, et al: MiR-150 promotes gastric cancer
proliferation by negatively regulating the pro-apoptotic gene EGR2.
Biochem Biophys Res Commun. 392:340–345. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Katada T, Ishiguro H, Kuwabara Y, Kimura
M, Mitui A, Mori Y, Ogawa R, Harata K and Fujii Y: microRNA
expression profile in undifferentiated gastric cancer. Int J Oncol.
34:537–542. 2009.PubMed/NCBI
|
|
24
|
Chen G, Tang Y, Wu JH and Liu FH: Role of
microRNAs in diagnosis and treatment of the pathogenesis of gastric
cancer. Int J Clin Exp Med. 7:5947–5957. 2014.
|
|
25
|
Jiang J, Zheng X, Xu X, Zhou Q, Yan H,
Zhang X, Lu B, Wu C and Ju J: Prognostic significance of miR-181b
and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin
or Doxifluridine/oxaliplatin. PLoS One. 6:e232712011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guo JX, Tao QS, Lou PR, Chen XC, Chen J
and Yuan GB: miR-181b as a potential molecular target for
anticancer therapy of gastric neoplasms. Asian Pac J Cancer Prev.
13:2263–2267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen L, Yang Q, Kong W-Q, Liu T, Liu M, Li
X and Tang H: MicroRNA-181b targets cAMP responsive element binding
protein 1 in gastric adenocarcinomas. IUBMB Life. 64:628–635. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu YJ and Fan Y: MiR-215/192 participates
in gastric cancer progression. Clin Transl Oncol. 17:34–40. 2015.
View Article : Google Scholar
|
|
29
|
Chen Q, Ge X, Zhang Y, Xia H, Yuan D, Tang
Q, Chen L, Pang X, Leng W and Bi F: Plasma miR-122 and miR-192 as
potential novel biomarkers for the early detection of distant
metastasis of gastric cancer. Oncol Rep. 31:1863–1870.
2014.PubMed/NCBI
|
|
30
|
Sun T, Yang M, Kantoff P and Lee GS: Role
of microRNA-221/-222 in cancer development and progression. Cell
Cycle. 8:2315–2316. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang J, Liu S, Sun GP, Wang F, Zou YF,
Jiao Y, Ning J and Xu J: Prognostic significance of
microRNA-221/222 expression in cancers: Evidence from 1,204
subjects. Int J Biol Markers. 29:e129–e141. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu K, Li G, Fan C, Diao Y, Wu B and Li J:
Increased expression of MicroRNA-221 in gastric cancer and its
clinical significance. J Int Med Res. 40:467–474. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F,
Xiao Y, Guang-Xiu W, Zhi-Fan J, Pei-Yu P, Qing-Yu Z and Chun-Sheng
K: MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell
proliferation and radioresistance by targeting PTEN. BMC Cancer.
10:3672010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mao S, He N, Xin L, Zeng F and Cao J:
Effect of antisense miR-224 on gastric cancer cell proliferation
and apoptosis. Zhonghua Zhong Liu Za Zhi. 36:92–96. 2014.(In
Chinese). PubMed/NCBI
|
|
35
|
Liu H, Li P, Li B, Sun P, Zhang J, Wang B
and Jia B: RKIP suppresses gastric cancer cell proliferation and
invasion and enhances apoptosis regulated by microRNA-224. Tumour
Biol. 35:10095–10103. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tao K, Yang J, Guo Z, Hu Y, Sheng H, Gao H
and Yu H: Prognostic value of miR-221-3p, miR-342-3p and miR-491-5p
expression in colon cancer. Am J Transl Res. 6:391–401.
2014.PubMed/NCBI
|
|
37
|
Kim CH, Kim HK, Rettig RL, Kim J, Lee ET,
Aprelikova O, Choi IJ, Munroe DJ and Green JE: miRNA signature
associated with outcome of gastric cancer patients following
chemotherapy. BMC Med Genomics. 4:792011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu Y, Xing R, Zhang X, Dong W, Zhang J,
Yan Z, Li W, Cui J and Lu Y: miR-375 targets the p53 gene to
regulate cellular response to ionizing radiation and etoposide in
gastric cancer cells. DNA Repair (Amst). 12:741–750. 2013.
View Article : Google Scholar
|
|
39
|
Shen Q, Yao Q, Sun J, Feng L, Lu H, Ma Y,
Liu L, Wang F, Li J, Yue Y, et al: Downregulation of histone
deacetylase 1 by microRNA-520h contributes to the chemotherapeutic
effect of doxorubicin. FEBS Lett. 588:184–191. 2014. View Article : Google Scholar
|
|
40
|
Zhao Z, Zhang L, Yao Q and Tao Z: miR-15b
regulates cisplatin resistance and metastasis by targeting PEBP4 in
human lung adenocarcinoma cells. Cancer Gene Ther. 22:108–114.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun
S, Hong L, Liu J and Fan D: miR-15b and miR-16 modulate multidrug
resistance by targeting BCL2 in human gastric cancer cells. Int J
Cancer. 123:372–379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kim CH, Kim HK, Rettig RL, Kim J, Lee ET,
Aprelikova O, Choi IJ, Munroe DJ and Green JE: miRNA signature
associated with outcome of gastric cancer patients following
chemotherapy. BMC Med Genomics. 4:792011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li L, Zhou L, Li Y, Lin S and Tomuleasa C:
MicroRNA-21 stimulates gastric cancer growth and invasion by
inhibiting the tumor suppressor effects of programmed cell death
protein 4 and phosphatase and tensin homolog. J BUON. 19:228–236.
2014.PubMed/NCBI
|
|
44
|
Yang SM, Huang C, Li XF, Yu MZ, He Y and
Li J: miR-21 confers cisplatin resistance in gastric cancer cells
by regulating PTEN. Toxicology. 306:162–168. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu T, Tang H, Lang Y, Liu M and Li X:
MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by
targeting prohibitin. Cancer Lett. 273:233–242. 2009. View Article : Google Scholar
|
|
46
|
Huang D, Wang H, Liu R, Li H, Ge S, Bai M,
Deng T, Yao G and Ba Y: miRNA27a is a biomarker for predicting
chemosensitivity and prognosis in metastatic or recurrent gastric
cancer. J Cell Biochem. 115:549–556. 2014. View Article : Google Scholar
|
|
47
|
Peng Y, Guo JJ, Liu YM and Wu XL:
MicroRNA-34A inhibits the growth, invasion and metastasis of
gastric cancer by targeting PDGFR and MET expression. Biosci Rep.
34:342014. View Article : Google Scholar
|
|
48
|
Cao W, Yang W, Fan R, Li H, Jiang J, Geng
M, Jin Y and Wu Y: miR-34a regulates cisplatin-induce gastric
cancer cell death by modulating PI3K/AKT/survivin pathway. Tumour
Biol. 35:1287–1295. 2014. View Article : Google Scholar
|
|
49
|
Molina-Pinelo S, Carnero A, Rivera F,
Estevez-Garcia P, Bozada JM, Limon ML, Benavent M, Gomez J, Pastor
MD, Chaves M, et al: MiR-107 and miR-99a-3p predict chemotherapy
response in patients with advanced colorectal cancer. BMC Cancer.
14:6562014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang HJ, Ruan HJ, He XJ, Ma YY, Jiang XT,
Xia YJ, Ye ZY and Tao HQ: MicroRNA-101 is down-regulated in gastric
cancer and involved in cell migration and invasion. Eur J Cancer.
46:2295–2303. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Bu Q, Fang Y, Cao Y, Chen Q and Liu Y:
Enforced expression of miR-101 enhances cisplatin sensitivity in
human bladder cancer cells by modulating the cyclooxygenase-2
pathway. Mol Med Rep. 10:2203–2209. 2014.PubMed/NCBI
|
|
52
|
Fang Y, Shen H, Li H, Cao Y, Qin R, Long
L, Zhu X, Xie C and Xu W: miR-106a confers cisplatin resistance by
regulating PTEN/Akt pathway in gastric cancer cells. Acta Biochim
Biophys Sin (Shanghai). 45:963–972. 2013. View Article : Google Scholar
|
|
53
|
Zhang Y, Lu Q and Cai X: MicroRNA-106a
induces multidrug resistance in gastric cancer by targeting RUNX3.
FEBS Lett. 587:3069–3075. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wang S, Lv C, Jin H, Xu M, Kang M, Chu H,
Tong N, Wu D, Zhu H, Gong W, et al: A common genetic variation in
the promoter of miR-107 is associated with gastric adenocarcinoma
susceptibility and survival. Mutat Res. 769:35–41. 2014. View Article : Google Scholar
|
|
55
|
Zhang Z, Zhang L, Yin ZY, Fan XL, Hu B,
Wang LQ and Zhang D: miR-107 regulates cisplatin chemosensitivity
of A549 non-small cell lung cancer cell line by targeting cyclin
dependent kinase 8. Int J Clin Exp Pathol. 7:7236–7241. 2014.
|
|
56
|
Zuo QF, Zhang R, Li BS, Zhao YL, Zhuang Y,
Yu T, Gong L, Li S, Xiao B and Zou QM: MicroRNA-141 inhibits tumor
growth and metastasis in gastric cancer by directly targeting
transcriptional co-activator with PDZ-binding motif, TAZ. Cell
Death Dis. 6:e16232015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zhou X, Su J, Zhu L and Zhang G:
Helicobacter pylori modulates cisplatin sensitivity in gastric
cancer by down-regulating miR-141 expression. Helicobacter.
19:174–181. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wu XL, Cheng B, Li PY, Huang HJ, Zhao Q,
Dan ZL, Tian DA and Zhang P: MicroRNA-143 suppresses gastric cancer
cell growth and induces apoptosis by targeting COX-2. World J
Gastroenterol. 19:7758–7765. 2013. View Article : Google Scholar
|
|
59
|
Zhuang M, Shi Q, Zhang X, Ding Y, Shan L,
Shan X, Qian J, Zhou X, Huang Z, Zhu W, et al: Involvement of
miR-143 in cisplatin resistance of gastric cancer cells via
targeting IGF1R and BCL2. Tumour Biol. 36:2737–2745. 2015.
View Article : Google Scholar
|
|
60
|
Gao P, Xing AY, Zhou GY, Zhang TG, Zhang
JP, Gao C, Li H and Shi DB: The molecular mechanism of microRNA-145
to suppress invasion-metastasis cascade in gastric cancer.
Oncogene. 32:491–501. 2013. View Article : Google Scholar
|
|
61
|
Liu RL, Dong Y, Deng YZ, Wang WJ and Li
WD: Tumor suppressor miR-145 reverses drug resistance by directly
targeting DNA damage-related gene RAD18 in colorectal cancer.
Tumour Biol. 36:5011–5019. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Lei Y, Hu X, Li B, Peng M, Tong S, Zu X,
Wang Z, Qi L and Chen M: miR-150 modulates cisplatin
chemosensitivity and invasiveness of muscle-invasive bladder cancer
cells via targeting PDCD4 in vitro. Med Sci Monit. 20:1850–1857.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Boni V, Bitarte N, Cristobal I, Zarate R,
Rodriguez J, Maiello E, Garcia-Foncillas J and Bandres E:
miR-192/miR-215 influence 5-fluorouracil resistance through cell
cycle-mediated mechanisms complementary to its post-transcriptional
thymidilate synthase regulation. Mol Cancer Ther. 9:2265–2275.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Wang XW, Wu Y, Wang D and Qin ZF: MicroRNA
network analysis identifies key microRNAs and genes associated with
precancerous lesions of gastric cancer. Genet Mol Res.
13:8695–8703. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Deng H, Lv L, Li Y, Zhang C, Meng F, Pu Y,
Xiao J, Qian L, Zhao W, Liu Q, et al: miR-193a-3p regulates the
multi-drug resistance of bladder cancer by targeting the LOXL4 gene
and the oxidative stress pathway. Mol Cancer. 13:2342014.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Zhao Y, Li C, Wang M, Su L, Qu Y, Li J, Yu
B, Yan M, Yu Y, Liu B, et al: Decrease of miR-202-3p expression, a
novel tumor suppressor, in gastric cancer. PLoS One. 8:e697562013.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Ren J, Huang HJ, Gong Y, Yue S, Tang LM
and Cheng SY: MicroRNA-206 suppresses gastric cancer cell growth
and metastasis. Cell Biosci. 4:262014. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zheng Z, Yan D, Chen X, Huang H, Chen K,
Li G, Zhou L, Zheng D, Tu L and Dong XD: MicroRNA-206: Effective
inhibition of gastric cancer progression through the c-Met pathway.
PLoS One. 10:e01287512015. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Yan W, Wang S, Sun Z, Lin Y, Sun S, Chen J
and Chen W: Identification of microRNAs as potential biomarker for
gastric cancer by system biological analysis. BioMed Res Int.
2014:9014282014. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Maftouh M, Avan A, Funel N, Frampton AE,
Fiuji H, Pelliccioni S, Castellano L, Galla V, Peters GJ and
Giovannetti E: miR-211 modulates gemcitabine activity through
downregulation of ribonucleotide reductase and inhibits the
invasive behavior of pancreatic cancer cells. Nucleosides
Nucleotides Nucleic Acids. 33:384–393. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S,
Guo X, Wang B, Gang Y, Zhang Y, et al: MiR-218 inhibits invasion
and metastasis of gastric cancer by targeting the Robo1 receptor.
PLoS Genet. 6:e10008792010. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
He X, Xiao X, Dong L, Wan N, Zhou Z, Deng
H and Zhang X: MiR-218 regulates cisplatin chemosensitivity in
breast cancer by targeting BRCA1. Tumour Biol. 36:2065–2075. 2015.
View Article : Google Scholar
|
|
73
|
Wang H, Zhu LJ, Yang YC, Wang ZX and Wang
R: MiR-224 promotes the chemoresistance of human lung
adenocarcinoma cells to cisplatin via regulating G1/S
transition and apoptosis by targeting p21WAF1/CIP1. Br J
Cancer. 111:339–354. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Amankwatia EB, Chakravarty P, Carey FA,
Weidlich S, Steele RJ, Munro AJ, Wolf CR and Smith G: MicroRNA-224
is associated with colorectal cancer progression and response to
5-fluorouracil-based chemotherapy by KRAS-dependent and
-independent mechanisms. Br J Cancer. 112:1480–1490. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Zhou C, Li X, Zhang X, Liu X, Tan Z, Yang
C and Zhang J: microRNA-372 maintains oncogene characteristics by
targeting TNFAIP1 and affects NF-κB signaling in human gastric
carcinoma cells. Int J Oncol. 42:635–642. 2013.
|
|
76
|
Xu Y, Jin J, Liu Y, Huang Z, Deng Y, You
T, Zhou T, Si J and Zhuo W: Snail-regulated MiR-375 inhibits
migration and invasion of gastric cancer cells by targeting JAK2.
PLoS One. 9:e995162014. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Berghmans T, Ameye L, Willems L, Paesmans
M, Mascaux C, Lafitte JJ, Meert AP, Scherpereel A, Cortot AB,
Cstoth I, et al; European Lung Cancer Working Party. Identification
of microRNA-based signatures for response and survival for
non-small cell lung cancer treated with cisplatin-vinorelbine A
ELCWP prospective study. Lung Cancer. 82:340–345. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Yoon S, Han E, Choi YC, Kee H, Jeong Y,
Yoon J and Baek K: Inhibition of cell proliferation and migration
by miR-509-3p that targets CDK2, Rac1, and PIK3C2A. Mol Cells.
37:314–321. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Yao Y, Suo AL, Li ZF, Liu LY, Tian T, Ni
L, Zhang WG, Nan KJ, Song TS and Huang C: MicroRNA profiling of
human gastric cancer. Mol Med Rep. 2:963–970. 2009.PubMed/NCBI
|
|
80
|
To KKW, Robey RW, Knutsen T, Zhan Z, Ried
T and Bates SE: Escape from hsa-miR-519c enables drug-resistant
cells to maintain high expression of ABCG2. Mol Cancer Ther.
8:2959–2968. 2009. View Article : Google Scholar : PubMed/NCBI
|
